

MAY 11 2004

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/769,219
Filing Date	January 30, 2004
First Named Inventor	Edmund J. Moran
Art Unit	Not yet assigned 1621
Examiner Name	Not yet assigned S. Kumar
Attorney Docket Number	P-025-US4

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ³ (if known)			
SL	A1	US- 3,211,792	10-12-1965	Osbond et al.	
	A2	US- 3,875,233	04-01-1975	Bastian et al.	
	A3	US- 4,021,485	05-03-1977	Schromm et al.	
	A4	US- 4,304,721	12-08-1981	Fahrenholz et al.	
	A5	US- 6,362,371 B1	03-26-2002	Moran et al.	
	A6	US- 6,541,669 B1	04-01-2003	Moran et al.	
SL	A7	US- 6,593,497	07-15-2003	Choi et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ³ (if known)				
SL	B1	WO 99/64035 A1	12-16-1999	Advanced Medicine, Inc.		
	B2	EP 0 233 686 A2	08-26-1987	Beecham Group PLC		
	B3	CH 550 768 (in German with English abstract)	06-28-1974	Sandoz AG		
	B4	DE 1158 082 (in German with English abstract)	11-28-1963	Chemie Grünenthal G.m.b.H.		
	B5	DE 1215729 (in German with English abstract)	05-05-1966	Lentia G.m.b.H.		
	B6	GB 1,040,724	09-01-1966	Roessler et al.		
SL	B7	JP 10152460 (in Japanese with English abstract)	06-09-1998	Kissei Pharm Co Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SL	C1	Alvarez et al., "Structure-Activity Relationships among DI- and Tetramine Disulfides Related to Benextramine", J. Med. Chem., Vol. 30, No. 7, pp 1186-1193 (1987)	
	C2	Auterhoff et al., "Lehrbuch der Pharmazeutischen Chemie", 12th Edition. Stuttgart: Wiss. Verl.-Ges., pp 646-648 (1991) - In German	
	C3	Bastian et al., "Carbocyclic compounds", (5128p), Chemical Abstracts, Vol. 79, pp 433-434 (1973)	
	C4	Bastian, "Carbocyclic compounds", (104935f), Chemical Abstracts, Vol. 79, pp 400 (1973)	
SL	C5	Colella et al., "N,N'-Bis[2-(4-hydroxyphenyl)ethyl]polymethylene-diamines" (128069d), Chemical Abstracts, Vol. 79, pp 371-372 (1973)	

Examiner Signature

S. Kumar

Date Considered

2 7 05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/769,219
Filing Date	January 30, 2004
First Named Inventor	Edmund J. Moran
Art Unit	Not yet assigned 162
Examiner Name	Not yet assigned S. Kumar

Attorney Docket Number

P-025-US4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
8Y	C8	Machin et al., "B-Selective Adrenoceptor Antagonists. 2. 4-Ether-Linked Phenoxypropanotamines", J. Med. Chem., Vol 26, pp 1570-1576 (1983)	
	C7	Pinder et al., "Hexoprenaline: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Asthma", Drugs 14: 1-28 (1977),	
	C8	Schmid et al., "Bis(alkandiamine) derivatives", Chemical Abstracts, Vol. 63 (1965)	
	C9	Schromm et al., "Polymethylenediamines", Chemical Abstracts (57999x), Vol. 78, p 485 (1973)	
	C10	Stormann et al., "Die Stimulierende Wirksamkeit von Hexoprenalin auf verschiedene sympathische B-Rezeptoren", Arzneimittel-Forschung, 23(1), pp 30-38 (in German with English abstract) (1973)	
	C11	Wismayr et al., "N,N'-Bis-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-hexamethylenediamine, its optically active form and its salts", Chemical Abstracts (42149p), Vol. 74, pp 333 (1971)	
	C12	Wismayr et al., "N,N'-Bis[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-hexamethylenediamine and its salts", Chemical Abstracts (35405m), Vol. 75, pp 457-458 (1971)	
	C13	Wissmayr et al., "N,N'-bis[2-(3',4'-Dihydroxyphenyl)-2-hydroxyethyl]-hexamethylenediamine", Chemical Abstracts (14096s), Vol. 76, pp 347 (1972)	
W	C14	Zoelss et al., "Broncholytic N,N'-bis[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]diaminoalkanes", Chemical Abstracts (87813b), Vol. 74, pp 406 (1971)	

Examiner Signature

S. Kumar

Date Considered

2/7/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.